Comparison of clinicopathological features and treatments between pre- and postmenopausal female breast cancer patients – a retrospective study

Kocaöz, Servet; Körüklüoğlu, Birol; Parlak, Ömer; Doğan, Hayriye Tatlı; Erdoğan, Fazlı

doi:10.5114/pm.2019.85786

Cited by 11 publications

(9 citation statements)

References 30 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast cancer in postmenopausal women is widely known to be less aggressive than cancer in younger women [22].…”

Section: Resultsmentioning

confidence: 99%

Study of HER2 in Breast Cancer Disease

Mhmood¹,

Allwsh

2021

Egypt. J. Chem.

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase growth receptor protein, Positive HER2 status has been linked with aggressive tumor behavior and resistance to cytotoxic and endocrine therapies. Breast cancer is a complex disease and the major cause of mortality in women worldwide. There are several subtypes of breast cancer and many options for treatment. This study aimed to know the hormonal changes associated with HER2+ve breast cancer in pre and postmenopausal Iraqi women. This study included 80 healthy women and 78 newly diagnosed breast cancer patients, 35 postmenopausal and 43 premenopausal. Depending on the HER2 test the patients were divided into two groups, positive and negative. The group of patients with positive (HER2) test was adopted and the negative group was excluded. Our result shows that there are a significant decrease in progesterone and a non-significant increase in Estradiol, FSH, and LH in premenopausal HER2+ve breast cancer patients but there is a significant increase in estradiol, FSH, and LH in postmenopausal HER2 +ve breast cancer patients. There is a significant decrease in TSH within the normal range in both pre and postmenopausal patients compared with a control group. There is a significant negative relationship between progesterone, and FSH, a negative relationship between progesterone and LH in premenopausal patients with HER2 positive test. Also, there is a significant negative relationship between progesterone and TSH, a negative relationship between progesterone, estradiol, and FSH. And a positive relationship between progesterone and LH in postmenopausal patients with HER2 positive test.

show abstract

“…Breast cancer in postmenopausal women is widely known to be less aggressive than cancer in younger women [22].…”

Section: Resultsmentioning

confidence: 99%

Study of HER2 in Breast Cancer Disease

Mhmood¹,

Allwsh

2021

Egypt. J. Chem.

View full text Add to dashboard Cite

show abstract

“…Some of the strongest evidence of aging influencing cancer biomarkers comes from studies that have considered the menopause. For example, differences in tumor characteristics were examined among 428 pre- and post-menopausal women ( 251 ). Compared with post-menopausal women, pre-menopausal women had significantly larger tumors (21% of pre-menopausal women had tumors of >5cm of diameter vs. 12% of post-menopausal women, P = 0.047).…”

Section: The Relevance Of Aging and Lifestyle For Cancer Biomarker Prmentioning

confidence: 99%

A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling

et al. 2021

View full text Add to dashboard Cite

Breast cancer is the most common malignancy among women worldwide. Over the last four decades, diagnostic and therapeutic procedures have improved substantially, giving patients with localized disease a better chance of cure, and those with more advanced cancer, longer periods of disease control and survival. However, understanding and managing heterogeneity in the clinical response exhibited by patients remains a challenge. For some treatments, biomarkers are available to inform therapeutic options, assess pathological response and predict clinical outcomes. Nevertheless, some measurements are not employed universally and lack sensitivity and specificity, which might be influenced by tissue-specific alterations associated with aging and lifestyle. The first part of this article summarizes available and emerging biomarkers for clinical use, such as measurements that can be made in tumor biopsies or blood samples, including so-called liquid biopsies. The second part of this article outlines underappreciated factors that could influence the interpretation of these clinical measurements and affect treatment outcomes. For example, it has been shown that both adiposity and physical activity can modify the characteristics of tumors and surrounding tissues. In addition, evidence shows that inflammaging and immunosenescence interact with treatment and clinical outcomes and could be considered prognostic and predictive factors independently. In summary, changes to blood and tissues that reflect aging and patient characteristics, including lifestyle, are not commonly considered clinically or in research, either for practical reasons or because the supporting evidence base is developing. Thus, an aim of this article is to encourage an integrative phenomic approach in oncology research and clinical management.

show abstract

“…These molecular subtypes consist of: luminal A, luminal B, HER2-enriched, triple-negative (TN) and basal-like groups (8,9). Breast cancers of premenopausal and postmenopausal women have clinical and biological differences (10).…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Effects of Clinicopathological and Radiological Findings on Survival in Women Younger Than 40 Years and Older Than 55 Years of Age With Breast Cancer

ÖZDEMİR

Kocaöz

ÇOMÇALI

et al. 2023

SDÜ Tıp Fakültesi Dergisi

Self Cite

View full text Add to dashboard Cite

Objective: Tumors of women with breast cancer show clinical and biological differences depending on the hormonal changes that develop with age. Therefore, in this study, we compared the radiologic, and clinicopathological features of breast cancer patient’s < 40 age and ≥55 age. Material and Methods: The files of a total of 759 patients, including 92 patients under 40 aged, and 322 patients 55 aged and over who were operated on for breast cancer over a 10-year period, were retrospectively reviewed and Estrojen Reseptor (ER), Progesteron Reseptor (PR), Human epidermal growth factor receptor 2 (HER2), Lymphovascular invasion (LVI) status, presence of axillary lymph node metastasis (ALNM), multifocality, presence of Ductal Carsinoma İnsitu (DCIS) or Lobular Carsinoma İnsitu (LCIS), tumor size, tumor histopathological type, grade, and score were recorded. Results: In patients under the age of 40, the tumor is less localized in the upper-inner and lower-inner quadrants of the breast, multifocality is more common, most of them have dense breast structure, the histological grade of the tumor is higher, LVI and LNM are more common. It was found that they had ER receptor positivity and higher Ki-67 proliferation index (p

show abstract

Comparison of clinicopathological features and treatments between pre- and postmenopausal female breast cancer patients – a retrospective study

Cited by 11 publications

References 30 publications

Study of HER2 in Breast Cancer Disease

Study of HER2 in Breast Cancer Disease

A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling

Comparison of the Effects of Clinicopathological and Radiological Findings on Survival in Women Younger Than 40 Years and Older Than 55 Years of Age With Breast Cancer

Contact Info

Product

Resources

About